secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2021-07-28T23:59:59+00:00
Accession:  0001171843-21-005153
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst appoints Vincent Milano, ex-ViroPharma CEO, to Board of Directors
--------------------------------------------------------------------------

- Board expanded to nine directors; Milano elected effective July 26, 2021.
- Milano appointed to Audit and Finance Committees; initial grant of 66,667 stock options.
- Milano is CEO of Idera Pharmaceuticals and former chairman/CEO of ViroPharma (developer of Cinryze for HAE).
- He will receive compensation per director policy, including annual grants of 40,000 stock options.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000117184321005153/0001171843-21-005153-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000117184321005153/f8k_072821.htm
  HTML page:      https://secwatch.observer/filing/0001171843-21-005153

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer